Interviews

Sheila Arquette, RPh, director of Pharmacy Services for Independent Health, discusses developments in the specialty pharmacy landscape for stakeholders to monitor.

Mark A. Vineis, vice president of Specialty Pharmacy at Cardinal Health, discusses how the growing population of older Americans could impact the specialty pharmacy landscape.

Kevin James, RPh, MBA, vice president of Payer Strategy at US Bioservices, discusses lessons the specialty industry learned from the impact of high cost drug launches for hepatitis C and high cholesterol.

Erin Hohman, PharmD, BCPS, director of Clinical Pharmacy Services at Amber Pharmacy, discusses the relationship between limited distribution networks and specialty pharmacy.

Autumn Bagwell, PharmD, BCPS, clinical pharmacist at Vanderbilt Specialty Pharmacy, discusses how to address the challenge of access to high cost specialty medications.

Mark Tesell, PharmD, BCPS, clinical consultant pharmacist for UMass Medical School Clinical Pharmacy Services, discusses potential solutions for access to cholesterol lowering drugs to improve.

Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses how specialty pharmacies may need to alter current strategies with increasing attention on high drug costs.

Rebekah L. Hanson, PharmD, BCPS, BCACP, clinical pharmacist and assistant professor at the UIC College of Pharmacy, discusses the challenge of out-of-pocket spending and the impact on drug adherence.

Kevin James, RPh, MBA, vice president of payer strategy at US Bioservices, discusses challenges for patients in accessing specialty medications.

Jonathan Van Lare, PharmD, director of Clinical Services at Pharmacy Advantage, discusses challenges balancing the quality of care with the high cost of treatments.

Eric Peacock, co-founder and CEO of MyHealthTeams, how bringing the voice of patients to clinical research can enhance health care.

Lynette Bradley-Baker, PhD, RPh, vice president of public affairs and engagement of the American Association of Colleges of Pharmacy (AACP), discusses the pharmacy job placement efforts of the AACP.

Daniel P. Kus, BS Pharm, RPh, discusses how the growth of drug prices could impact the specialty pharmacy patient experience.

Lynette Bradley-Baker, PhD, RPh, vice president of public affairs and engagement of the American Association of Colleges of Pharmacy (AACP), explains how pharmacy associations work in collaboration.

Kevin James, RPh, MBA, vice president of payer strategy at US Bioservices, discusses how specialty pharmacies can navigate limited distribution networks.

Lynette Bradley-Baker, PhD, RPh, vice president of public affairs and engagement of the American Association of Colleges of Pharmacy (AACP), describes how pharmacy school curriculums have changed.

Lynette Bradley-Baker, PhD, RPh, vice president of public affairs and engagement of the American Association of Colleges of Pharmacy (AACP), discusses collaborations with the AACP.

Lynette Bradley-Baker, PhD, RPh, vice president of public affairs and engagement of the American Association of Colleges of Pharmacy (AACP), explains how pharmacies can become sites for student rotations.

Rebekah L. Hanson, PharmD, BCPS, BCACP, clinical pharmacist and assistant professor at the UIC College of Pharmacy, discusses medication management processes that can improve adherence to specialty therapies.

Lynette Bradley-Baker, PhD, RPh, vice president of public affairs and engagement of the American Association of Colleges of Pharmacy (AACP), explains how practicing pharmacists can become preceptors.

Marc O'Connor, COO and chief strategy officer at Curant Health, discusses actions that can enhance the relationship between manufacturers, payers, providers and patients in specialty pharmacy.

Lynette Bradley-Baker, PhD, RPh, vice president of public affairs and engagement of the American Association of Colleges of Pharmacy (AACP), discusses how students can engage with the AACP.

Erin Hohman, PharmD, BCPS, director of Clinical Pharmacy Services at Amber Pharmacy, discusses access to cholesterol-lowering PCSK9 inhibitors and whether the hype regarding the impact of these medications was overblown.

Marc O'Connor, COO and chief strategy officer at Curant Health, discusses the out-of-pocket costs that can emerge for patients starting a specialty medication regimen.

Mark Tesell, PharmD, BCPS, clinical consultant pharmacist at UMass Medical School, discusses the treatment switch from statins to PCSK9 inhibitors in patients with high cholesterol.

Jonathan Van Lare, PharmD, director of Clinical Services at Pharmacy Advantage, discusses the impact of oncology medications and how specialty pharmacies can adjust.

Mark A. Vineis, vice president of Specialty Pharmacy of Cardinal Health, discusses how the increased interest of the federal government in escalating drug prices may impact specialty pharmacy.

Paul LeVine, vice president of Analytic Services at TrialCard, discusses how specialty pharmacies can use patient feedback surveys to improve treatment outcomes.

Autumn Bagwell, PharmD, BCPS, clinical pharmacist at Vanderbilt Specialty Pharmacy, discusses the components of an effective patient management program to optimize adherence.

Sheila Arquette, RPh, director of Pharmacy Services at Independent Health, discusses the challenges of access to high cost specialty medications.